Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment.
Methods: From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated.
Results: The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6-66.8%] in the curative group, and 25.1% (95% CI 11.5-38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177-0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis.
Conclusions: Curative treatment can prolong survival in selected patients with intermediate-stage HCCs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11604-017-0628-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Surgical strategy for repeated metastasectomy for advanced colorectal cancer with synchronous liver metastases.
Surg Today
September 2025
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8588, Japan.
Purpose: Liver metastases from colorectal cancer (CRLM) are a major determinant of the prognosis of metastatic colorectal cancer. Although curative resection is recommended for resectable CRLM, recurrence remains a challenge and the criteria for patient selection and repeat resection are still unclear. We conducted this study to evaluate the outcomes of metastatic lesion resection with curative intent (R0 resection), to identify the factors associated with recurrence, and to establish the feasibility of repeat metastasectomy.
View Article and Find Full Text PDFFrom stem cell transplantation to stem cell-based drug delivery systems targeting hematological malignancies: recent advances and clinical considerations.
Expert Opin Drug Deliv
September 2025
Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, PR China.
Introduction: Hematopoietic stem cell transplantation (HSCT) is a promising treatment option for hematological malignancies. Despite its curative potential, it faces clinical challenges, including relapse and graft-versus-host disease (GVHD). Systemic toxicity due to chemotherapy is a significant problem in patients with hematological malignancies.
View Article and Find Full Text PDFAdjuvant Chemotherapy for Patients With Chronic Kidney Disease: A Study on Treatment Adoption and Associated Factors.
Cancer Med
September 2025
Division of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Introduction: Patients with chronic kidney disease (CKD) face unique challenges in cancer treatment, including the need for chemotherapy dose adjustments and avoiding nephrotoxic agents, often leading to less aggressive treatment. However, little is known about the real-world administration of adjuvant chemotherapy for patients with CKD. In this study, we aimed to investigate the prevalence of adjuvant chemotherapy in patients with CKD and to explore factors influencing chemotherapy use.
View Article and Find Full Text PDFPrognostic Impact of Bone Mineral Density Reduction During Neoadjuvant Chemotherapy (NAC) in Patients Undergoing NAC Followed by Esophagectomy for Esophageal Cancer.
Ann Gastroenterol Surg
September 2025
Division of Gastrointestinal Surgery, Department of Surgery Jikei University School of Medicine Tokyo Japan.
Background: Our previous study suggested that low bone mineral density (BMD), known as osteopenia, was a poor prognostic factor in patients who underwent esophagectomy for esophageal cancer (EC).Meanwhile, the association between BMD reduction during neoadjuvant chemotherapy (NAC) and the worse prognosis remains unknown, although esophagectomy after NAC is the first option for the treatment of advanced esophageal squamous cell carcinoma (ESCC). Therefore, this study intended to investigate the prognostic impact of BMD reduction during NAC.
View Article and Find Full Text PDFSalvage esophagectomy for unresectable locally advanced esophageal squamous cell carcinoma: Significant or not?
Ann Gastroenterol Surg
September 2025
We reviewed the current status and perspectives on salvage esophagectomy for initially unresectable locally advanced esophageal squamous cell carcinoma (ESCC) in the era of minimally invasive surgery and immunotherapy. Although the standard treatment for these patients is definitive chemoradiotherapy (CRT), the complete response rate to CRT alone remains unsatisfactory. Salvage esophagectomy, which is defined as surgery for residual or recurrent lesions after definitive CRT, is considered a curative treatment in clinical practice.
View Article and Find Full Text PDF